Product Description: Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities[1][2].
Applications: Cancer-Kinase/protease
Formula: N/A
References: [1]Min Yan, et al. Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: A single-arm, multicenter, phase 2 study. Journal of Clinical Oncology. 2022. 40 (16), e13030-e13030. /[2]Deng L,et al. Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers. Open Life Sci. 2023 Jan 10;18(1):20220535.
Molecular Weight: N/A
Compound Purity: 96.54
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: EGFR